Monitoring the clinical outcomes in advanced prostate cancer: What imaging modalities and other markers are reliable?

Seminars in Oncology

Volumn 40, Issue 3, 2013, Pages 375-392

  Morris, Michael J ^a,b   Autio, Karen A ^a   Basch, Ethan M ^a   Danila, Daniel C ^a,b   Larson, Steven ^a   Scher, Howard I ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; CABAZITAXEL; CABOZANTINIB; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; ORTERONEL; PLACEBO; PREDNISONE; RUXOLITINIB; TECHNETIUM 99M;

ARTICLE; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; HUMAN; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER;

BONE AND BONES; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; NEOPLASTIC CELLS, CIRCULATING; PAIN MANAGEMENT; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84879448375     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.04.008     Document Type: Article

References (102)

1. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
2. G.A. Gignac, M.J. Morris, G. Heller, L.H. Schwartz, and H.I. Scher Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel Cancer 113 2008 966 974
3. H.I. Scher, M.J. Morris, W.K. Kelly, L.H. Schwartz, and G. Heller Prostate cancer clinical trial end points: RECISTing a step backwards Clin Cancer Res 11 2005 5223 5232
4. G.J. Bubley, M. Carducci, and W. Dahut Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 17 1999 3461 3467
5. S. Halabi, A.J. Armstrong, A.O. Sartor, J.S. De Bono, E.B. Kaplan, and E.J. Small Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy J Clin Oncol 30 suppl May 20 2012 abstract 4515
6. W.K. Kelly, H.I. Scher, M. Mazumdar, V. Vlamis, M. Schwartz, and S.D. Fossa Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer J Clin Oncol 11 1993 607 615
7. D.P. Petrylak, D.P. Ankerst, and C.S. Jiang Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16 J Natl Cancer Inst 98 2006 516 521
8. D.A. Verbel, G. Heller, W.K. Kelly, and H.I. Scher Quantifying the amount of variation in survival explained by prostate-specific antigen Clin Cancer Res 8 2002 2576 2579
9. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
10. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
11. de J.S. Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
12. de J.S. Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
13. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
14. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 2001 89 95
15. US Food and Drug Administration. Draft guidance for industry: standards for clinical trial imaging endpoints. Issued August 2011. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM268555.pdf. Accessed March 12, 2013.
16. J. Cummings, F. Raynaud, L. Jones, R. Sugar, and C. Dive Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs Br J Cancer 103 2010 1313 1317
17. US Food and Drug Administration. Draft guidance for industry: qualification process for drug development tools. Issued October 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM230597.pdf. Accessed March 13, 2013.
18. H.I. Scher, S. Halabi, and I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
19. W.D. Johns, M.B. Garnick, and W.D. Kaplan Leuprolide therapy for prostate cancer. An association with scintigraphic flare on bone scan Clin Nucl Med 15 1990 485 487
20. J.J. Pollen, and W.J. Shlaer Osteoblastic response to successful treatment of metastatic cancer of the prostate AJR Am J Roentgenol 132 1979 927 931
21. P.H. Smith, and A. Bono Calais da Silva F, et al. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853 The EORTC Urological Group. Cancer 66 1990 1009 1016
22. C.J. Ryan, S. Shah, and E. Efstathiou Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response Clin Cancer Res 17 2011 4854 4861
23. M.J. Morris, J.S. Farrelly, and J.J. Fox The Prostate Cancer Clinical Trials Consortium (PCCTC) bone scan data capture tool for clinical trials using Prostate Cancer Working Group 2 (PCWG2) criteria: effect on data accuracy and workload. 2011 ASCO Genitourinary Cancers Symposium J Clin Oncol 29 suppl 7 2011 abstract 121
24. C.J. Ryan, M. Morris, and A. Molina Association of radiographic progression-free survival (rPFS) adapted from Prostate Cancer Working Group 2 (PCWG2) consensus criteria (APCWG2) with overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): results from COU-AA-302. 37th Congress of the European Society for Medical Oncology Ann Oncol 23 suppl 9 2012 ix294 abstract 894O
25. D.C. Smith, M.R. Smith, and C. Sweeney Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial J Clin Oncol 31 2013 412 419
26. M. Imbriaco, S.M. Larson, and H.W. Yeung A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index Clin Cancer Res 4 1998 1765 1772
27. E.R. Dennis, X. Jia, and I.S. Mezheritskiy Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer J Clin Oncol 30 2012 519 524
28. M.S. Brown, G.H. Chu, and H.J. Kim Computer-aided quantitative bone scan assessment of prostate cancer treatment response Nucl Med Commun 33 2012 384 394
29. D. Ulmert, R. Kaboteh, and J.J. Fox A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index Eur Urol 62 2012 78 84
30. R.L. Wahl, H. Jacene, Y. Kasamon, and M.A. Lodge From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors J Nucl Med 50 Suppl 1 2009 122S 150S
31. G. Segall, D. Delbeke, and M.G. Stabin SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0 J Nucl Med 51 2010 1813 1820
32. A. Costeas, H.Q. Woodard, and J.S. Laughlin Depletion of 18F from blood flowing through bone J Nucl Med 11 1970 43 45
33. F.D. Grant, F.H. Fahey, A.B. Packard, R.T. Davis, A. Alavi, and S.T. Treves Skeletal PET with 18F-fluoride: applying new technology to an old tracer J Nucl Med 49 2008 68 78
34. D.A. Weber, E.J. Greenberg, and A. Dimich Kinetics of radionuclides used for bone studies J Nucl Med 10 1969 8 17
35. M. Blau, R. Ganatra, and M.A. Bender 18 F-fluoride for bone imaging Semin Nucl Med 2 1972 31 37
36. R. Wootton, and C. Dore The single-passage extraction of 18F in rabbit bone Clin Phys Physiol Meas 7 1986 333 343
37. R.K. Doot, M. Muzi, and L.M. Peterson Kinetic analysis of 18F-fluoride PET images of breast cancer bone metastases J Nucl Med 51 2010 521 527
38. M.L. Frost, G.M. Blake, and S.J. Park-Holohan Long-term precision of 18F-fluoride PET skeletal kinetic studies in the assessment of bone metabolism J Nucl Med 49 2008 700 707
39. W.K. Hsu, M.S. Virk, B.T. Feeley, D.B. Stout, A.F. Chatziioannou, and J.R. Lieberman Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET/CT J Nucl Med 49 2008 414 421
40. Schirrmeister H, Glatting G, Hetzel J, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800-4.
41. FDA approves production of imaging agent that helps detect prostate cancer. Press release; September 9, 2012. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm319201.htm. Accessed March 13, 2013.
42. M.J. Morris, T. Akhurst, and S.M. Larson Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy Clin Cancer Res 11 2005 3210 3216
43. H.I. Scher, T.M. Beer, and C.S. Higano Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 2010 1437 1446
44. S.M. Larson, M. Morris, and I. Gunther Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer J Nucl Med 45 2004 366 373
45. P.B. Zanzonico, R. Finn, and K.S. Pentlow PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer J Nucl Med 45 2004 1966 1971
46. FDA/NCI/CMS Oncology Biomarker Qualification Initiative. Memorandum of understanding between the FDA, NCI, and CMS for the FDA/NCI/CMS Oncology Biomarker Qualification Initiative. Document MOU 225-06-8001. January 2006. Last updated March 10, 2009. http://www.fda.gov/AboutFDA/PartnershipsCollaborations/ MemorandaofUnderstandingMOUs/DomesticMOUs/ucm115681.htm. Accessed March 13, 2013.
47. M.S. Pepe, R. Etzioni, and Z. Feng Phases of biomarker development for early detection of cancer J Natl Cancer Inst 93 2001 1054 1061
48. US Food and Drug Administration. Guidance for industry: bioanalytical method validation. Issued May 2001. http://www.fda.gov/downloads/Drugs/./ Guidances/ucm070107.pdf. Accessed March 13, 2013.
49. US Food and Drug Administration. Guidance for industry: E16 biomarkers related to drug or biotechnology product development: context, structure, and format of qualification submissions. Issued August 2011. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM267449.pdf. Accessed March 13, 2013.
50. T.R. Ashworth A case of cancer in which cells similar to those in the tumours were seen in the blood after death Aust Med J 14 1869 146 149
51. W.J. Allard, J. Matera, and M.C. Miller Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases Clin Cancer Res 10 2004 6897 6904
52. D.R. Shaffer, M.A. Leversha, and D.C. Danila Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer Clin Cancer Res 13 2007 2023 2029
53. S. Paget The distribution of secondary growths in cancer of the breast Lancet 133 1889 571 573
54. FDA Clearance Document for Veridex LLC. CellSearch(TM) Circulating Tumor Cell Kit. Premarket notification - expanded indications for use - metastatic prostate cancer. February 26, 2008. http://www.accessdata.fda.gov/cdrh-docs/ pdf7/K073338.pdf. Accessed March 15, 2013.
55. G.T. Budd, M. Cristofanilli, and M.J. Ellis Circulating tumor cells versus imaging - predicting overall survival in metastatic breast cancer Clin Cancer Res 12 2006 6403 6409
56. M. Cristofanilli, G.T. Budd, and M.J. Ellis Circulating tumor cells, disease progression, and survival in metastatic breast cancer N Engl J Med 351 2004 781 791
57. M. Cristofanilli, D.F. Hayes, and G.T. Budd Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer J Clin Oncol 23 2005 1420 1430
58. D.F. Hayes, M. Cristofanilli, and G.T. Budd Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival Clin Cancer Res 12 2006 4218 4224
59. S.J. Cohen, C.J. Punt, and N. Iannotti Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer J Clin Oncol 26 2008 3213 3221
60. S.J. Cohen, C.J. Punt, and N. Iannotti Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer Ann Oncol 20 2009 1223 1229
61. D.C. Danila, G. Heller, and G.A. Gignac Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer Clin Cancer Res 13 2007 7053 7058
62. J.S. de Bono, H.I. Scher, and R.B. Montgomery Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin Cancer Res 14 2008 6302 6309
63. H.I. Scher, X. Jia, and J.S. de Bono Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data Lancet Oncol 10 2009 233 239
64. F.A. Coumans, S.T. Ligthart, J.W. Uhr, and L.W. Terstappen Challenges in the enumeration and phenotyping of CTC Clin Cancer Res 18 2012 5711 5718
65. G. Attard, J.F. Swennenhuis, and D. Olmos Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2009 2912 2918
66. G.M. Cann, Z.G. Gulzar, and S. Cooper mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer PLoS One 7 2012 e49144
67. M.A. Leversha, J. Han, and Z. Asgari Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer Clin Cancer Res 15 2009 2091 2097
68. N. Mitsiades, C.C. Sung, and N. Schultz Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors Cancer Res 72 2012 6142 6152
69. O.B. Goodman Jr, L.M. Fink, and J.T. Symanowski Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors Cancer Epidemiol Biomarkers Prev 18 2009 1904 1913
70. M.Y. Kim, T. Oskarsson, and S. Acharyya Tumor self-seeding by circulating cancer cells Cell 139 2009 1315 1326
71. V. Muller, N. Stahmann, and S. Riethdorf Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity Clin Cancer Res 11 2005 3678 3685
72. M. Gonen, and G. Heller Concordance probability and discriminative power of proportional hazards regression Biometrika 92 2005 965 970
73. R. Gentlemen, and J. Crowley Graphical methods for censored data J Am Stat Assoc 86 1991 678 683
74. S. Halabi, E.J. Small, and P.W. Kantoff Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer J Clin Oncol 21 2003 1232 1237
75. D.C. Danila, M.J. Morris, and JS de Bono Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer J Clin Oncol 28 2010 1496 1501
76. A.H. Reid, G. Attard, and D.C. Danila Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate J Clin Oncol 28 2010 1489 1495
77. H.I. Scher, G. Heller, and A. Molina Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. ASCO Annual Meeting J Clin Oncol 29 suppl May 20 2011 abstract LBA4517
78. S.R. Barthel, D.L. Hays, and E.M. Yazawa Definition of molecular determinants of prostate cancer cell bone extravasation Cancer Res 73 2013 942 952
79. J. Hannemann, S. Meyer-Staeckling, and D. Kemming Quantitative high-resolution genomic analysis of single cancer cells PLoS One 6 2011 e26362
80. A.H. Reid, G. Attard, and L. Ambroisine Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer Br J Cancer 102 2010 678 684
81. Coumans FA, Doggen CJ, Attard G, de Bono JS, Terstappen LW, All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer. Ann Oncol. 2010;21:1851-7.
82. T.M. Gorges, I. Tinhofer, and M. Drosch Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition BMC Cancer 12 2012 178
83. D.C. Danila, A. Anand, and C.C. Sung TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate Eur Urol 60 2011 897 904
84. I.F. Tannock, D. Osoba, and M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764
85. US Food and Drug Administration. Guidance for industry: Patient-reported outcomes measures: use in medical product development to support labeling claims. Issued December 2009. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed March 15, 2013.
86. E. Basch Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels Value Health 15 2012 401 403
87. C. Harrison, J.J. Kiladjian, and H.K. Al-Ali JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis N Engl J Med 366 2012 787 798
88. Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. JAMA 307 2012 1636 1640
89. H.I. Scher, K. Fizazi, and F. Saad Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
90. C. Parker, D. Heinrich, and J.M. O'Sullivan Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases J Clin Oncol 30 suppl 5 2012
91. C.J. Logothetis, E. Basch, and A. Molina Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial Lancet Oncol 13 2012 1210 1217
92. Zytiga (abiraterone acetate) tablets prescribing information. Horsham, PA: Janssen Biotech, Inc; December 2012. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/202379s005lbl.pdf. Accessed March 14, 2013.
93. C.J. Ryan, M.R. Smith, and JS de Bono Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
94. J.T. Farrar What is clinically meaningful: outcome measures in pain clinical trials Clin J Pain 16 2000 S106 S112
95. J.T. Farrar, R.K. Portenoy, J.A. Berlin, J.L. Kinman, and B.L. Strom Defining the clinically important difference in pain outcome measures Pain 88 2000 287 294
96. J.T. Farrar, R.H. Dworkin, and M.B. Max Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable J Pain Symptom Manage 31 2006 369 377
97. P.W. Kantoff, S. Halabi, and M. Conaway Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study J Clin Oncol 17 1999 2506 2513
98. Basch E, Bennett AV, Scher HI. Cabozantinib (XL184) reduces pain symptoms in patients with castration resistant prostate cancer (CRPC) and bone metastases: results from a phase 2 non-randomized expansion cohort. In: Proceedings of the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Mol Cancer Ther. 2011;10(11 Suppl): abstract B7.
99. A.V. Bennett, R.E. Jensen, and E. Basch Electronic patient-reported outcome systems in oncology clinical practice CA Cancer J Clin 62 2012 337 347
100. C.F. Snyder, N.K. Aaronson, and A.K. Choucair Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations Qual Life Res 21 2012 1305 1314
101. A.P. Abernethy, J.E. Herndon 2nd, and J.L. Wheeler Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology J Pain Symptom Manage 37 2009 1027 1038
102. Fisch MJ, Lee JW, Weiss M, et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol. 2012;30:1980-8.